XML 24 R13.htm IDEA: XBRL DOCUMENT v3.21.2
Shareholders' Equity
 9 Months Ended
Sep. 30, 2021
Shareholders' Equity  
Shareholders' Equity

8. Shareholders' Equity

 

 

 

Three months ended September 30,

 


Nine months ended September 30,

 

 

2021

 

 

2020

 


2021

2020

Common stock and additional paid-in capital

 

 

 

 

 

 

 

 









Balance, beginning of period

 

$

63,450

 

 

$

58,597

 


$ 63,378

$ 58,537
Issuance of common stock and warrants, net

                9,288


          4,764


9,288


4,764

Share-based compensation expense

 

 

35

 

 

 

1

 



100


55

Proceeds from employee stock purchase plan

 

 

5

 

 

 

5

 



12


11

Balance, end of period

 

$

72,778

 

 

$

63,367

 


$ 72,778

$ 63,367

 

 

 

 

 

 

 

 

 









Accumulated other comprehensive loss

 

 

 

 

 

 

 

 









Balance, beginning of period

 

$

(213

 )

 

$

(211

)


$ (186 )
$ (176 )

Unrealized loss on available-for-sale securities, net of tax 

 

 

(8

 )

 

 

4

(13 )

11

Foreign currency translation adjustment

 

 

(4

 )

 

 

17

(26 )

(25 )

Balance, end of period

 

$

(225

 )

 

$

(190

)


$ (225 )
$ (190 )

 

 

 

 

 

 

 

 

 









Accumulated deficit

 

 

 

 

 

 

 

 









Balance, beginning of period

 

$

(16,619

 )

 

$

(17,667

 )
$ (13,378 )
$ (13,883 )

Net loss

 

 

(2,169

 )

 

 

(1,260

)



(5,410 )

(5,044 )

Balance, end of period

 

$

(18,788

 )

 

$

(18,927

)


$ (18,788 )
$ (18,927 )

 

 

 

 

 

 

 

 

 









Total shareholders' equity

 

$

53,765

 

 

$

44,250

 


$ 53,765

$ 44,250

 

Issue of Common Stock and Warrants


On September 13, 2020, the Company entered into a securities purchase agreement with certain purchasers named therein, pursuant to which the Company issued and sold in a registered direct offering 2,116,050 shares of the Company's common stock, par value $0.001 per share at an offering price of $2.4925 per share. The Company received gross proceeds of approximately $5,275 and net proceeds $4,764 after deducting placement agent fees and related offering expenses. In a concurring private placement, the Company also issued to the same purchasers warrants exercisable for an aggregate of 1,058,025 shares of common stock at an exercise price of $2.43 per share. Each warrant became immediately exercisable and will expire five years from the issuance date. 


On  September 12, 2021, the Company entered into a securities purchase agreement with certain purchasers named therein, pursuant to which the Company issued 3,623,189 shares of the Company's common stock, par value $0.001 per share at an offering price of $2.76 per share. The Company received gross proceeds of approximately $10,000 and net proceeds of $9,288 after deducting placement agent fees and related offering expenses. In a concurring private placement the Company also issued to the same purchasers warrants exercisable for an aggregate of 3,623,189 shares of common stock at an exercise price of $2.76 per share. Each warrant became immediately exercisable and will expire on March 15, 2027.